SecBot SecBot
8-K ·Filed Mar 19, 2026

SABS

SAB Biotherapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed8mo ago SEC0001193125-26-114730
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The significant equity issuance at a market cap of only $2 million suggests severe dilution for existing shareholders. Traders should monitor how the market prices this dilution against the potential value of the SAB-142 clinical program, particularly as the company advances its Phase 2b trial for type 1 diabetes.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.78
T+0 close · Mar 19, 2026 · via day close
Latest settled
+3.17%
T+60 · $3.90
Vs SPY
−11.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $3.78entry
  2. T+1 · 8mo ago −0.79%α +0.95% · $3.75
  3. T+5 · 8mo ago +1.32%α +3.53% · $3.83
  4. T+20 · 7mo ago +1.85%α −5.77% · $3.85
  5. T+60 · 5mo ago +3.17%α −11.17% · $3.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-funded warrants to purchase up to 2.8 million shares at $3.85 per share, with an option for underwriters to purchase up to an additional 3.3 million shares. The company expects to raise approximately $69.7 million in net proceeds (up to $81.7 million if the option is exercised), which will be used primarily to fund clinical development of its lead product candidate SAB-142 for type 1 diabetes.

Key Financial Metrics

Deal Value
$85.0M

Key Facts

  • Offering includes 19,324,677 shares of common stock and pre-funded warrants for 2,753,246 shares at $3.85 per share
  • Underwriters have a 30-day option to purchase up to 3,311,688 additional shares
  • Expected net proceeds of $69.7 million ($81.7 million if option exercised), after underwriting discounts and expenses
  • Proceeds will be used to fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes
  • Company has a market cap of only $2 million despite raising significant capital

Financial Impact

Approximately $69.7 million in net proceeds ($81.7 million maximum) through issuance of 22.1 million shares (up to 25.4 million with option) and warrants for 2.8 million shares

cashdilutionequity

Risk Factors

  • Extreme shareholder dilution from issuing over 22 million new shares
  • Low market cap of $2 million indicates limited market confidence despite capital raise
  • Clinical-stage biotech with unproven technology and no commercial products

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-114730
Document: sabs-ex4_1.htm0001193125-26-114730
Document: sabs-20260317.htm0001193125-26-114730
Document: sabs-ex5_1.htm0001193125-26-114730
Document: sabs-ex99_2.htm0001193125-26-114730
Document: sabs-ex99_1.htm0001193125-26-114730
Document: 0001193125-26-114730-index-headers.html0001193125-26-114730
Document: 0001193125-26-114730-index.html0001193125-26-114730
Document: 0001193125-26-114730.txt0001193125-26-114730

Track record

15 reports on SABS

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  4. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
  5. Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
  6. Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
  8. Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
  9. May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
  10. May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026